ArticleBritish journal of pharmacology2021
STAT3/NF-κB signalling disruption in M2 tumour-associated macrophages is a major target of PLGA nanocarriers/PD-L1 antibody immunomodulatory therapy in breast cancer.
Rômulo S Cavalcante et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
46 papers cite it
this papercites it